2020
Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients
Thombs B, Kwakkenbos L, Carrier M, Bourgeault A, Tao L, Harb S, Gagarine M, Rice D, Bustamante L, Ellis K, Duchek D, Wu Y, Bhandari P, Neupane D, Carboni-Jiménez A, Henry R, Krishnan A, Sun Y, Levis B, He C, Turner K, Benedetti A, Culos-Reed N, El-Baalbaki G, Hebblethwaite S, Bartlett S, Dyas L, Patten S, Varga J, Team S, Fortuné C, Gietzen A, Guillot G, Lewis N, Nielsen K, Richard M, Sauvé M, Welling J, Investigators S, Baron M, Furst D, Gottesman K, Malcarne V, Mayes M, Mouthon L, Nielson W, Riggs R, Wigley F, Assassi S, Boutron I, Ells C, van den Ende C, Fligelstone K, Frech T, Godard D, Harel D, Hinchcliff M, Hudson M, Johnson S, Larche M, Leite C, Nguyen C, Pope J, Portales A, Rannou F, Reyna T, Schouffoer A, Suarez-Almazor M, Agard C, Albert A, André M, Arsenault G, Benzidia I, Bernstein E, Berthier S, Bissonnette L, Boire G, Bruns A, Carreira P, Casadevall M, Chaigne B, Chung L, Cohen P, Correia C, Dagenais P, Denton C, Domsic R, Dubois S, Dunne J, Dunogue B, Fare R, Farge-Bancel D, Fortin P, Gill A, Gordon J, Granel-Rey B, Gyger G, Hachulla E, Hatron P, Herrick A, Hij A, Hoa S, Ikic A, Jones N, de B. Fernandes A, Kafaja S, Khalidi N, Lambert M, Launay D, Liang P, Maillard H, Maltez N, Manning J, Marie I, Martin M, Martin T, Masetto A, Maurier F, Mekinian A, Melchor S, Nikpour M, Olagne L, Poindron V, Proudman S, Régent A, Rivière S, Robinson D, Rodriguez E, Roux S, Smets P, Smith D, Sobanski V, Spiera R, Steen V, Stevens W, Sutton E, Terrier B, Thorne C, Varga J, Wilcox P, Ayala M, Ostbo N. Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. Journal Of Psychosomatic Research 2020, 135: 110132. PMID: 32521358, PMCID: PMC7224675, DOI: 10.1016/j.jpsychores.2020.110132.Peer-Reviewed Original ResearchConceptsContagious disease outbreaksWaitlist controlPositive COVID-19 testPre-existing medical conditionsSymptoms of depressionSymptoms of anxietyLeast mild anxietyDisease outbreaksCOVID-19 testMental health outcomesMental health consequencesPrimary outcomeEligible participantsPragmatic RCTCohort participantsIntervention groupScleroderma patientsIntervention participantsMedical conditionsPhysical activitySPIN CohortRisk individualsHealth outcomesRCT designSecondary objective
2019
Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study
Scott MKD, Quinn K, Li Q, Carroll R, Warsinske H, Vallania F, Chen S, Carns MA, Aren K, Sun J, Koloms K, Lee J, Baral J, Kropski J, Zhao H, Herzog E, Martinez FJ, Moore BB, Hinchcliff M, Denny J, Kaminski N, Herazo-Maya JD, Shah NH, Khatri P. Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study. The Lancet Respiratory Medicine 2019, 7: 497-508. PMID: 30935881, PMCID: PMC6529612, DOI: 10.1016/s2213-2600(18)30508-3.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisPulmonary fibrosisAbsolute monocyte countMonocyte countImmune cell typesElectronic health recordsPoor outcomeHigh riskSystemic sclerosisMonocyte percentageHypertrophic cardiomyopathyHigh absolute monocyte countPeripheral blood mononuclear cell samplesComplete blood count valuesSpecific immune cell typesTransplant-free survivalMulticentre cohort studyHealth recordsHigh-risk patientsBlood count valuesSame clinical presentationHigher monocyte countMononuclear cell samplesRisk of mortalityCell types
2012
Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis.
Hinchcliff M, Desai CS, Varga J, Shah SJ. Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis. Clinical And Experimental Rheumatology 2012, 30: s30-7. PMID: 22338601, PMCID: PMC3507505.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedChicagoChi-Square DistributionComorbidityDiastoleEchocardiography, DopplerFemaleHumansLinear ModelsMaleMiddle AgedMultivariate AnalysisPrevalencePrognosisProportional Hazards ModelsProspective StudiesRegistriesRetrospective StudiesRisk AssessmentRisk FactorsScleroderma, SystemicSystoleTime FactorsVentricular Dysfunction, LeftVentricular Function, LeftConceptsLV diastolic dysfunctionLeft ventricular diastolic dysfunctionVentricular diastolic dysfunctionDiastolic dysfunctionRisk of deathSystemic sclerosisDisease durationEarly mitral annular velocityMultivariable Cox regression analysisSSc disease durationTissue Doppler eLV systolic dysfunctionPulmonary function testsMitral annular velocityCoronary artery diseaseCox regression analysisMultivariable linear regressionSystemic hypertensionSystolic dysfunctionClinical characteristicsDoppler EImpaired relaxationArtery diseaseClinical factorsConsecutive patients